IRONWOOD PHARMACEUTICALS, INC. Shareholders' Equity
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Shareholders' Equity of -$161.84 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent -$161.84M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$217.14M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$261.83M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$264.16M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | -$161.84M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$217.14M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$261.83M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$264.16M 10-Q · filed 2025-11-10 |
| 2025-06-30 | -$308.16M 10-Q · filed 2025-08-11 |
| 2025-03-31 | -$334.05M 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$301.33M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$311.33M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$321.73M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$330.52M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$346.30M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$323.22M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$345.70M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $706.85M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $652.38M 10-K · filed 2024-02-16 |
| 2022-09-30 | $591.06M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $532.88M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $517.78M 10-Q · filed 2022-08-04 |
| 2021-12-31 | $605.91M 10-K · filed 2023-02-16 |
| 2021-09-30 | $579.94M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $511.76M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $110.19M 10-Q · filed 2022-08-04 |
| 2020-12-31 | $62.64M 10-Q · filed 2022-08-04 |
| 2020-09-30 | $5.90M 10-Q · filed 2021-11-04 |
| 2020-06-30 | -$36.85M 10-Q · filed 2021-11-04 |
| 2020-03-31 | -$71.56M 10-Q · filed 2021-11-04 |
| 2019-12-31 | -$93.25M 10-K · filed 2022-02-18 |
| 2019-09-30 | -$153.05M 10-Q · filed 2020-11-05 |
| 2019-06-30 | -$219.37M 10-Q · filed 2020-11-05 |
| 2019-03-31 | -$237.18M 10-Q · filed 2020-11-05 |
| 2018-12-31 | -$196.37M 10-K · filed 2022-02-18 |
| 2018-09-30 | -$197.29M 10-Q · filed 2019-10-31 |
| 2018-06-30 | -$43.95M 10-Q · filed 2019-10-31 |
| 2018-03-31 | -$18.05M 10-Q · filed 2019-10-31 |
| 2017-12-31 | $9.85M 10-K · filed 2021-02-17 |
| 2017-09-30 | -$17.58M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $4.87M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $29.64M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $66.72M 10-K · filed 2020-02-13 |
| 2016-09-30 | $59.46M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $81.38M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $90.94M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $95.13M 10-K · filed 2019-02-25 |
| 2015-09-30 | $100.46M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $140.28M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $68.16M 10-Q · filed 2015-05-06 |
| 2014-12-31 | $88.55M 10-K · filed 2018-02-22 |
| 2014-09-30 | $108.15M 10-Q · filed 2014-11-05 |
| 2014-06-30 | $141.83M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $188.94M 10-Q · filed 2014-04-29 |
| 2013-12-31 | $38.23M 10-K · filed 2017-02-22 |
| 2013-09-30 | $84.21M 10-Q · filed 2013-10-28 |
| 2013-06-30 | $139.42M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $58.52M 10-Q · filed 2013-04-23 |
| 2012-12-31 | $144.05M 10-K · filed 2016-02-19 |
| 2012-09-30 | $182.11M 10-Q · filed 2012-11-06 |
| 2012-06-30 | $128.78M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $164.15M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $109.86M 10-K · filed 2015-02-18 |
| 2010-12-31 | $159.55M 10-K · filed 2014-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |